Use and Awareness of Heated Tobacco Products in Europe.


Journal

Journal of epidemiology
ISSN: 1349-9092
Titre abrégé: J Epidemiol
Pays: Japan
ID NLM: 9607688

Informations de publication

Date de publication:
05 03 2022
Historique:
pubmed: 19 1 2021
medline: 12 3 2022
entrez: 18 1 2021
Statut: ppublish

Résumé

Heated tobacco products (HTP) are new forms of tobacco consumption with limited information available on their use among the general population. Our objective was to analyze the prevalence and associations of use of HTP across 11 countries in Europe. Within the TackSHS Project, in 2017-2018 we conducted a cross-sectional study with information on HTP use in the following countries: Bulgaria, England, France, Germany, Greece, Italy, Latvia, Poland, Portugal, Romania and Spain. In each country, face-to-face interviews were performed on a representative sample of around 1,000 subjects aged ≥15 years, for a total of 10,839 subjects. Overall, 27.8% of study participants were aware of HTPs, 1.8% were ever HTP users (ranging from 0.6% in Spain to 8.3% in Greece), and 0.1% were current users. Men were more frequently HTP ever users than women (adjusted odds ratio [aOR] 1.47; 95% confidence interval [CI], 1.11-1.95). Ever HTP use was inversely related to age (P for trend <0.001) and more frequent in ex-smokers (compared with never smokers, aOR 4.32; 95% CI, 2.69-6.95) and current smokers (aOR 8.35; 95% CI, 5.67-12.28), and in electronic cigarette past users (compared with never users, aOR 5.48; 95% CI, 3.46-8.68) and current users (aOR 5.92; 95% CI, 3.73-9.40). In 2017-2018, HTP use was still limited in Europe among the general population; however, the dual use of these products, their high use among younger generations, and the interest of non-smokers in these products are worrying and indicate the need for close monitoring in terms of prevalence and the characteristics of users.

Sections du résumé

BACKGROUND
Heated tobacco products (HTP) are new forms of tobacco consumption with limited information available on their use among the general population. Our objective was to analyze the prevalence and associations of use of HTP across 11 countries in Europe.
METHODS
Within the TackSHS Project, in 2017-2018 we conducted a cross-sectional study with information on HTP use in the following countries: Bulgaria, England, France, Germany, Greece, Italy, Latvia, Poland, Portugal, Romania and Spain. In each country, face-to-face interviews were performed on a representative sample of around 1,000 subjects aged ≥15 years, for a total of 10,839 subjects.
RESULTS
Overall, 27.8% of study participants were aware of HTPs, 1.8% were ever HTP users (ranging from 0.6% in Spain to 8.3% in Greece), and 0.1% were current users. Men were more frequently HTP ever users than women (adjusted odds ratio [aOR] 1.47; 95% confidence interval [CI], 1.11-1.95). Ever HTP use was inversely related to age (P for trend <0.001) and more frequent in ex-smokers (compared with never smokers, aOR 4.32; 95% CI, 2.69-6.95) and current smokers (aOR 8.35; 95% CI, 5.67-12.28), and in electronic cigarette past users (compared with never users, aOR 5.48; 95% CI, 3.46-8.68) and current users (aOR 5.92; 95% CI, 3.73-9.40).
CONCLUSIONS
In 2017-2018, HTP use was still limited in Europe among the general population; however, the dual use of these products, their high use among younger generations, and the interest of non-smokers in these products are worrying and indicate the need for close monitoring in terms of prevalence and the characteristics of users.

Identifiants

pubmed: 33456019
doi: 10.2188/jea.JE20200248
pmc: PMC8824661
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

139-144

Auteurs

Silvano Gallus (S)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.

Alessandra Lugo (A)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.

Xiaoqiu Liu (X)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.
The George Institute for Global Health.

Elisa Borroni (E)

Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.

Luke Clancy (L)

TobaccoFree Research Institute Ireland.

Giuseppe Gorini (G)

Istituto per lo Studio, la Prevenzione e la Rete Oncologica.

Maria José Lopez (MJ)

Agència de Salut Pública de Barcelona.
CIBER en Epidemiología y Salud Pública (CIBERESP) (Biomedical Research Centre Network for Epidemiology and Public Health).
Institut d'investigació Biomèdica Sant Pau (IIB St. Pau).

Anna Odone (A)

Department of Public Health, Experimental and Forensic Medicine, University of Pavia.
IRCCS San Raffaele Scientific Institute.

Krzysztof Przewozniak (K)

The Maria Sklodowska-Curie National Research Institute of Oncology.
Collegium Civitas.
Foundation "Smart Health - Health in 3D".

Olena Tigova (O)

Tobacco Control Unit, Institut Català d'Oncologia, L'Hospitalet de Llobregat.
Tobacco Control Research Group, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat.
Biomedical Research Centre Network for Respiratory Diseases for Respiratory Diseases (Centro de Investigación Biomédica en Red en Enfermedades respiratorias, CIBERES).
School of Medicine and Health Sciences, Universitat de Barcelona, L'Hospitalet de Llobregat.

Piet A van den Brandt (PA)

Department of Epidemiology, CAPHRI-School for Public Health and Primary Care, Maastricht University Medical Centre.
Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre.

Constantine Vardavas (C)

Hellenic Cancer Society.

Esteve Fernandez (E)

Tobacco Control Unit, Institut Català d'Oncologia, L'Hospitalet de Llobregat.
Tobacco Control Research Group, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat.
Biomedical Research Centre Network for Respiratory Diseases for Respiratory Diseases (Centro de Investigación Biomédica en Red en Enfermedades respiratorias, CIBERES).
School of Medicine and Health Sciences, Universitat de Barcelona, L'Hospitalet de Llobregat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH